Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Gene therapy in dogs shows hope for muscular dystrophy
Labrador
In the study, dogs - which have a similar body size to that of a diseased boy - were injected with the disease when they were two to three months old.

Researchers on the cusp of having a treatment for the disease

A team of researchers have successfully treated dogs with muscular dystrophy using gene therapy. The treatment could pave the the way for clinical trials in humans within the next few years.

The study, published in the journal Human Molecular Genetics, demonstrates for the first time that a common virus can deliver the microgene, which protects against the virus, to all muscles in that of diseased dog.

Muscular dystrophy affects around 250,000 people in the USA and occurs when damaged muscle tissue is replaced with fibrous, fatty or bony tissue and loses function.

Patients with the disease have a gene mutation that disrupts the production of a protein known as 'dystrophin". This is one of the largest genes in the human body and its absence can eventually lead to muscle cell degeneration and death.

Study leader Dongsheg Duan from the University of Missouri explains: “Due to its size, it is impossible to deliver the entire gene with a gene therapy vector, which is the vehicle that carries the therapeutic gene to the correct site in the body.

“Through previous research, we were able to develop a miniature version of this gene called a microgene. This minimised dystrophin protected all muscles in the body of diseased mice.”

In the study, dogs - which have a similar body size to that of a diseased boy - were injected with the disease when they were two to three months old and just starting to show signs of muscular dystrophy.  The dogs are now six to seven months old and continue to develop normally.

“The virus we are using is one of the most common viruses; it is also a virus that produces no symptoms in the human body, making this a safe way to spread the dystrophin gene throughout the body,” added Duan.

“These dogs develop muscular dystrophy naturally in a similar manner as humans. It’s important to treat DMD early before the disease does a lot of damage as this therapy has the greatest impact at the early stages in life.”

Margaret Proctor Mulligan from the University of Missouri's School of Medicine said: “This discovery took our research team more than 10 years, but we believe we are on the cusp of having a treatment for the disease.”

Become a member or log in to add this story to your CPD history

Vets launch new podcast for pet owners

News Story 1
 Two independent vets have launched a podcast to help owners strengthen their bond with pets. Dr Maggie Roberts and Dr Vanessa Howie, who have worked in both veterinary practice and major charities, are keen to use their experience to enable people to give pets a better life.

The venture, called Vets Talking Pets, provides advice and information on a range of topics, including how to select a suitable pet, where to obtain them and how to get the best out of your vet. Maggie and Vanessa will also discuss sensitive subjects, including end-of-life care, raw food diets and the cost of veterinary care.

The podcast can be found on all the usual podcast sites, including Podbean, Apple, Amazon Music and YouTube. 

Click here for more...
News Shorts
RCVS Regional Question Time heads to Edinburgh

The RCVS is to bring its Regional Question Time (RQT) to Edinburgh for 2026.

The event will take place at Novotel Edinburgh Park in Edinburgh on Wednesday, 20 May 2026.

It will begin with supper and drinks at 6.30pm, with an evening programme from 7.30pm. This will start with an update on RCVS' activities, followed by questions and answers with representatives.

RCVS is encouraging an 'open dialogue', in which queries can be raised in a friendly, informal environment.

While discussions are expected to be audience-led, the RQT is expected address major issues including the VSA, the CMA's remedy package and the VN Vision project.

Tim Parkin, RCVS president, said: "It's an important time for the professions, and I'm looking forward to meeting colleagues in Scotland as we navigate this period of change together so we can come out stronger."

Tickets can be booked here.